company background image
ALM logo

Almirall BME:ALM Stock Report

Last Price

€9.01

Market Cap

€1.9b

7D

-0.4%

1Y

4.6%

Updated

15 Feb, 2025

Data

Company Financials +

Almirall, S.A.

BME:ALM Stock Report

Market Cap: €1.9b

ALM Stock Overview

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. More details

ALM fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends1/6

Rewards

Trading at 64.9% below our estimate of its fair value

Earnings are forecast to grow 45.47% per year

Analysts in good agreement that stock price will rise by 31.2%

Risk Analysis

No risks detected for ALM from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Almirall, S.A. Competitors

Laboratorios Farmaceuticos Rovi

BME:ROVI

€2.8b

Faes Farma

BME:FAE

€1.1b

Laboratorio Reig Jofre

BME:RJF

€212.2m

Labiana Health

BME:LAB

€21.1m

Price History & Performance

Summary of share price highs, lows and changes for Almirall
Historical stock prices
Current Share Price€9.01
52 Week High€10.04
52 Week Low€7.85
Beta0.41
1 Month Change2.97%
3 Month Change7.78%
1 Year Change4.65%
3 Year Change-15.16%
5 Year Change-28.89%
Change since IPO-39.93%

Recent News & Updates

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear

Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Recent updates

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively

Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear

Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Is Almirall (BME:ALM) A Risky Investment?

May 16
Is Almirall (BME:ALM) A Risky Investment?

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Mar 29
Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Jan 04
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01
An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14
Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01
Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06
Is Almirall (BME:ALM) Using Too Much Debt?

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23
Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Shareholder Returns

ALMES PharmaceuticalsES Market
7D-0.4%-1.1%2.3%
1Y4.6%-7.3%27.5%

Return vs Industry: ALM exceeded the Spanish Pharmaceuticals industry which returned -7.3% over the past year.

Return vs Market: ALM underperformed the Spanish Market which returned 27.5% over the past year.

Price Volatility

Is ALM's price volatile compared to industry and market?
ALM volatility
ALM Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement3.5%
Market Average Movement3.3%
10% most volatile stocks in ES Market6.6%
10% least volatile stocks in ES Market0.8%

Stable Share Price: ALM has not had significant price volatility in the past 3 months compared to the Spanish market.

Volatility Over Time: ALM's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19431,996Carlos Gallardo Piquéwww.almirall.com

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Almirall, S.A. Fundamentals Summary

How do Almirall's earnings and revenue compare to its market cap?
ALM fundamental statistics
Market cap€1.92b
Earnings (TTM)-€44.87m
Revenue (TTM)€953.49m

2.0x

P/S Ratio

-42.9x

P/E Ratio

Is ALM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALM income statement (TTM)
Revenue€953.49m
Cost of Revenue€255.10m
Gross Profit€698.39m
Other Expenses€743.26m
Earnings-€44.87m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 24, 2025

Earnings per share (EPS)-0.21
Gross Margin73.25%
Net Profit Margin-4.71%
Debt/Equity Ratio23.6%

How did ALM perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

-107%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 07:09
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Almirall, S.A. is covered by 32 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elena FernándezAhorro Corporación
Guilherme SampaioBanco BPI, S.A.
Álvaro Arístegui EchevarríaBanco de Madrid S.A.U.